Syndax Pharmaceuticals, Inc.
SNDX
$18.79
-$0.33-1.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -311.58M | -334.99M | -331.20M | -318.76M | -297.06M |
| Total Depreciation and Amortization | 3.00K | 2.00K | 5.00K | 8.00K | 11.00K |
| Total Amortization of Deferred Charges | 259.00K | 197.00K | 142.00K | 30.00K | -- |
| Total Other Non-Cash Items | 40.81M | 36.49M | 32.23M | 30.55M | 26.09M |
| Change in Net Operating Assets | -40.37M | -4.36M | 12.31M | 13.27M | 12.09M |
| Cash from Operations | -310.88M | -302.67M | -286.52M | -274.90M | -258.86M |
| Capital Expenditure | -131.00K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -60.38M | -46.10M | -26.23M | -219.78M | 32.91M |
| Cash from Investing | -60.52M | -46.10M | -26.23M | -219.78M | 32.91M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.53M | 8.35M | 8.48M | 9.72M | 264.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 343.65M | 343.65M | 343.65M | 343.65M | -- |
| Cash from Financing | 355.18M | 352.00M | 352.13M | 353.37M | 264.43M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.21M | 3.24M | 39.38M | -141.31M | 38.47M |